Part of: Coronavirus vaccine inequality
Back to package

Poor countries seen missing out as rich nations hoard COVID-19 vaccines

by Thin Lei Win | Thomson Reuters Foundation
Wednesday, 9 December 2020 00:01 GMT

A phial of the Pfizer/BioNTech COVID-19 vaccine is seen ahead of being administered at Belfast's Royal Victoria Hospital, Northern Ireland, on the first day of the largest immunisation programme in British history, December 8, 2020. Liam McBurney/Pool via REUTERS

Image Caption and Rights Information

Nine out of 10 people in dozens of poor countries may not be vaccinated next year as rich nations snap up supplies, campaigners warn

By Thin Lei Win

Dec 9 (Thomson Reuters Foundation) - Nine out of 10 people in dozens of poor nations could miss out on getting vaccinated against COVID-19 next year because rich countries have hoarded far more doses than they need, campaigners said on Wednesday.

Rich nations home to 14% of the global population had bought 53% of the total stock of the most-promising vaccines as of last month, said the People's Vaccine Alliance, a coalition including Oxfam, Amnesty International and Global Justice Now.

They said pharmaceutical companies working on COVID-19 vaccines should openly share their technology and intellectual property through the World Health Organisation (WHO) so more doses can be manufactured.

"This shouldn't be a battle between countries to secure enough doses," Mohga Kamal-Yanni, an advisor for People's Vaccine Alliance, told the Thomson Reuters Foundation.

"During these unprecedented times of a global pandemic, people's lives and livelihoods should be put before pharmaceutical company profit," she added.

While high-risk groups in Britain received on Tuesday the first shot of the vaccine developed by Pfizer and BioNTech, most people in 67 low- and lower middle-income countries including Bhutan, Ethiopia and Haiti, risk being left behind, they said.

Among the three COVID-19 vaccines for which efficacy results have been announced, almost all the available doses of two of them - Moderna and Pfizer/BioNTech - have been acquired by rich countries, the Alliance report said.

While AstraZeneca and the University of Oxford have pledged to provide 64% of their doses to people in developing nations, that would only reach 18% of the world's population by next year "at most", it added.

The campaigners used data from science information and analytics company Airfinity to analyse the deals done between countries and eight leading vaccine candidates, including China's Sinovac and Russia's Sputnik V.

The EU, United States, Britain, Canada, Japan, Switzerland, Australia, Hong Kong, Macau, New Zealand, Israel and Kuwait have acquired 53% of these potential doses - with Canada buying enough to vaccinate its population five times over, Oxfam said.

"By buying up the vast majority of the world's vaccine supply, rich countries are in breach of their human rights obligations," Steve Cockburn, Amnesty International's Head of Economic and Social Justice, said in a statement.

Related stories:

Pfizer, Moderna, AstraZeneca: Which COVID-19 vaccine could reach developing countries first?

Vaccinating the world: Lessons learned from India, Haiti and Sierra Leone

Ensuring global COVID-19 vaccine access seen worth billions to rich nations

(Reporting By Thin Lei Win @thinink; Editing by Helen Popper (Please credit the Thomson Reuters Foundation, the charitable arm of Thomson Reuters, that covers the lives of people around the world who struggle to live freely or fairly. Visit http://news.trust.org)

Our Standards: The Thomson Reuters Trust Principles.